Innogene Kalbiotech Pte Ltd (Innogene) is a drug development company specializing in oncology, intensive care and therapeutic and prophylactic vaccines. The Company is advancing late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of Glioma and various types of head and neck cancer; and already marketing critical care and biosimilars product.
RECENT DEVELOPMENT
Nimotuzumab was presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL. Click the link for download:
- Preliminary results of an escalating dose phase
I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination
with external radiotherapy in patients diagnosed with stage IIb, III or IV non-small
cell lung cancer unsuitable for radical therapy.
Gwyn Bebb, Anthony Brade, Colum Smith, Stewart Rorke and Igor Sherman.
download
- Pharmacodynamic Study of Nimotuzumab, An Anti-Epidermal
Growth Factor Receptor (EGFR) Monoclonal Antibody, In Patients With Unresectable
Squamous Cell Carcinoma of The Head and Neck: A Sendo Foundation Study results
F. Rojo, E. Gracias, N. Villena, T. Cruz, I. Corradino, M. Cedeño,
C. Campas, C. Sessa, T. Crombet, J. Albanell. download
- Phase III trial of Nimotuzumab for the treatment
of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents.
Bode, M. Windelberg, M. Massimino, E. Khuhlaeva, M. Warmuth-Metz, R.D. Kortmann,
F. Bach, G. Fleischhack. download
Listen to Dr. Ferdinand Bach�s Interview on TheraCIM (Nimotuzumab) with Radio Singapore International (April 2008) listen here
Watch David Allan�s German TV Interview on Deutsches Anleger
Fernsehen (February 2008) listen
here